XML 59 R49.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION- Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Revenue $ 745,145 $ 648,833
ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue 48,977 35,262
Net product revenues    
Disaggregation of Revenue [Line Items]    
Revenue 734,644 637,815
Marketed by Company | Products excluding ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue 685,667 602,553
Marketed by Company | Products excluding ALDURAZYME | United States    
Disaggregation of Revenue [Line Items]    
Revenue 241,694 192,999
Marketed by Company | Products excluding ALDURAZYME | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 229,578 195,748
Marketed by Company | Products excluding ALDURAZYME | Latin America    
Disaggregation of Revenue [Line Items]    
Revenue 88,282 78,594
Marketed by Company | Products excluding ALDURAZYME | Rest of world    
Disaggregation of Revenue [Line Items]    
Revenue 126,113 135,212
Marketed by Sanofi | ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue $ 48,977 $ 35,262